ReviewResearch and practice in thrombosis and haemostasis2026
Venous thromboembolism in China: epidemiology, management strategies, and future directions.
Review in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (VTE) is one of the leading causes of unexpected death among hospitalized patients. It is also a preventable condition, and its incidence can be substantially reduced through active and effective prophylaxis. In recent years, the burden of VTE in China has continued to increase, driven by population aging, a rising prevalence of malignancy, a growing volume of complex surgery, and advances in imaging and laboratory testing. At present, the clinical management paradigm for VTE in China has gradually evolved from the traditional acute event-centered 'diagnosis-treatment' pathway to a hospital-based closed-loop management model. This model covers risk assessment, prevention, diagnosis, treatment, follow-up, and quality evaluation across the entire continuum of care. Based on the latest Chinese guidelines, expert consensus statements, and representative studies, this review summarizes the epidemiologic characteristics, prevention strategies, diagnostic pathways, treatment patterns, management of special populations, and future research directions of VTE in China. Overall, VTE management in China has begun to develop into an integrated framework. It starts with risk assessment in hospitalized patients, centers on standardized prophylaxis and risk-stratified diagnosis, extends to individualized anticoagulation strategies and management of special populations, and is supported by quality control and digital tools. Further efforts are still needed to improve precise risk stratification, specialty-specific clinical pathways, laboratory standardization, inpatient management, and long-term management. These advances will help move VTE management in China from standardization to precision and from in-hospital prevention to whole-course care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.